Michael H Davidson

Summary

Affiliation: Radiant Research
Country: USA

Publications

  1. pmc Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study
    Michael H Davidson
    Department of Medicine, Division of Cardiology, Pritzker School of Medicine, The University of Chicago, 515 N State St, Ste 2700, Chicago, IL 60654, USA
    Arterioscler Thromb Vasc Biol 30:1873-6. 2010
  2. pmc Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes
    Susan Sam
    Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, Illinois, USA
    Diabetes Care 32:932-7. 2009
  3. doi request reprint Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease
    Michael H Davidson
    Radiant Research and University of Chicago, Chicago, IL, USA
    Am J Cardiol 104:936-42. 2009
  4. doi request reprint Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study
    Michael H Davidson
    The University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Clin Ther 31:2824-38. 2009
  5. pmc Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes
    Susan Sam
    Department of Medicine, University of Illinois at Chicago, 1819 West Polk Street, Chicago, Illinois 60612, USA
    J Clin Endocrinol Metab 97:E110-4. 2012
  6. pmc Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes
    Susan Sam
    Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Illinois, Chicago, Illinois
    Diabetes Care 32:1916-20. 2009
  7. doi request reprint Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists
    Michael H Davidson
    University of Chicago Pritzker School of Medicine, Chicago, IL 60610, USA
    J Clin Lipidol 5:338-67. 2011
  8. doi request reprint Apolipoprotein measurements: is more widespread use clinically indicated?
    Michael H Davidson
    Preventive Cardiology Center, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Clin Cardiol 32:482-6. 2009
  9. ncbi request reprint Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study
    Richard H Karas
    Division of Cardiology, Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA
    Am J Cardiovasc Drugs 8:69-81. 2008
  10. doi request reprint The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk
    Sandeep S Mangalmurti
    Division of Cardiology, The University of Chicago Pritzker School of Medicine, 515 State Street, Suite 2700, Chicago, IL 60654, USA
    Curr Atheroscler Rep 13:373-80. 2011

Detail Information

Publications84

  1. pmc Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study
    Michael H Davidson
    Department of Medicine, Division of Cardiology, Pritzker School of Medicine, The University of Chicago, 515 N State St, Ste 2700, Chicago, IL 60654, USA
    Arterioscler Thromb Vasc Biol 30:1873-6. 2010
    ..To compare coronary artery calcium (CAC) progression between 2 treatment groups, pioglitazone versus glimepiride...
  2. pmc Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes
    Susan Sam
    Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, Illinois, USA
    Diabetes Care 32:932-7. 2009
    ..We examined the relationships between VAT and SAT and systemic inflammatory markers in a large well-characterized cohort of subjects with type 2 diabetes...
  3. doi request reprint Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease
    Michael H Davidson
    Radiant Research and University of Chicago, Chicago, IL, USA
    Am J Cardiol 104:936-42. 2009
    ....
  4. doi request reprint Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study
    Michael H Davidson
    The University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Clin Ther 31:2824-38. 2009
    ..Coadministration of statin and fenofibrate monotherapies is frequently used to treat patients with dyslipidemia; however, a fixed-dose combination (FDC) tablet is not currently marketed...
  5. pmc Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes
    Susan Sam
    Department of Medicine, University of Illinois at Chicago, 1819 West Polk Street, Chicago, Illinois 60612, USA
    J Clin Endocrinol Metab 97:E110-4. 2012
    ..In animal and observational studies, adiponectin is associated with lipoprotein risk factors for cardiovascular disease...
  6. pmc Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes
    Susan Sam
    Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Illinois, Chicago, Illinois
    Diabetes Care 32:1916-20. 2009
    ..Greater accumulation of visceral fat is strongly linked to risk of cardiovascular disease. However, elevated waist circumference by itself does not always identify individuals with increased visceral fat...
  7. doi request reprint Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists
    Michael H Davidson
    University of Chicago Pritzker School of Medicine, Chicago, IL 60610, USA
    J Clin Lipidol 5:338-67. 2011
    ....
  8. doi request reprint Apolipoprotein measurements: is more widespread use clinically indicated?
    Michael H Davidson
    Preventive Cardiology Center, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Clin Cardiol 32:482-6. 2009
    ....
  9. ncbi request reprint Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study
    Richard H Karas
    Division of Cardiology, Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA
    Am J Cardiovasc Drugs 8:69-81. 2008
    ..This fact has focused increased attention on treating abnormalities of non-high-density lipoprotein-cholesterol (non-HDL-C), HDL-C, and triglycerides in national guidelines and has intensified interest in combination therapy...
  10. doi request reprint The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk
    Sandeep S Mangalmurti
    Division of Cardiology, The University of Chicago Pritzker School of Medicine, 515 State Street, Suite 2700, Chicago, IL 60654, USA
    Curr Atheroscler Rep 13:373-80. 2011
    ....
  11. ncbi request reprint Relationship of traditional and nontraditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes
    Theodore Mazzone
    Section of Diabetes and Metabolism MC 797, University of Illinois at Chicago, 1819 W Polk Street, Chicago, IL 60612, USA
    Diabetes 56:849-55. 2007
    ..Adiposity measures are significantly associated with coronary artery calcium score, but their importance may be largely explained by apolipoprotein B or triglyceride-rich lipoprotein cholesterol...
  12. pmc Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes
    Susan Sam
    Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, Chicago, Illinois, USA
    Diabetes 57:2022-7. 2008
    ..Insulin resistance and type 2 diabetes are associated with an atherogenic lipoprotein profile. We examined the role of visceral and subcutaneous fat depots, independent of BMI, on the dyslipidemia associated with type 2 diabetes...
  13. doi request reprint Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy
    Tamar S Polonsky
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637 1470, USA
    Am J Cardiol 101:27B-35B. 2008
    ..In this article, the authors review the use of combination therapy as a strategy for risk reduction in CAD...
  14. doi request reprint Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines
    Michael H Davidson
    Preventive Cardiology Center, Pritzker School of Medicine, University of Chicago, 515 North State Street, Chicago, IL 60610, USA
    Am J Cardiol 101:51F-57F. 2008
    ..However, at this time Lp-PLA(2) cannot be recommended as a target of therapy...
  15. ncbi request reprint Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome
    Michael H Davidson
    Radiant Research, Chicago, Illinois, USA
    Am J Cardiol 93:3C-11C. 2004
    ..This article reviews emerging therapeutic strategies for the management of dyslipidemia in patients with the MS...
  16. ncbi request reprint Combination lipid-lowering therapy in diabetes
    Michael H Davidson
    Chicago Center for Clinical Research, Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, IL 60612, USA
    Curr Diab Rep 3:263-8. 2003
    ..For diabetic patients who require additional LDL lowering, ezetimibe may provide a safe combination to a statin to achieve the LDL goal of less than 100 mg/dL...
  17. ncbi request reprint Combination therapy for dyslipidemia: safety and regulatory considerations
    Michael H Davidson
    Chicago Center for Clinical Research, Rush Medical College, Chicago, Illinois 60612, USA
    Am J Cardiol 90:50K-60K. 2002
    ..This article discusses several safety and regulatory considerations for the use of combination therapy for dyslipidemia...
  18. doi request reprint Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2)
    Michael H Davidson
    University of Chicago, Chicago, IL, USA
    Am J Cardiol 111:1131-8. 2013
    ....
  19. ncbi request reprint Effects of high-fiber oat and wheat cereals on postprandial glucose and lipid responses in healthy men
    Kevin C Maki
    Radiant Research, Chicago, IL, USA
    Int J Vitam Nutr Res 77:347-56. 2007
    ..64 +/- 0.91 vs. 3.38 +/- 0.98 hours x mmol/L, p = 0.018). These results suggest that high-fiber oat cereal influenced postprandial triglyceride and free fatty acid levels, which may have implications regarding cardiovascular disease risk...
  20. ncbi request reprint Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet
    Michael H Davidson
    University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Clin Drug Investig 28:615-23. 2008
    ....
  21. doi request reprint Lp-PLA2: A new target for statin therapy
    Lynne T Braun
    Rush Heart and Vascular Institute, Rush University Medical Center, 1725 W Harrison, Suite 1159, Chicago, IL 60612, USA
    Curr Atheroscler Rep 12:29-33. 2010
    ..A large morbidity and mortality trial was recently initiated to evaluate the long-term safety and efficacy of darapladib, an Lp-PLA(2) antagonist, in patients with high-risk coronary heart disease...
  22. ncbi request reprint Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications
    Michael H Davidson
    University of Chicago Pritzker School of Medicine, Chicago, IL 60610, USA
    Cleve Clin J Med 75:479-82, 486-8, 490-1. 2008
  23. doi request reprint Statin and ezetimibe combination therapy in cardiovascular disease
    Ewa Dembowski
    Section of Cardiology, The University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Curr Opin Endocrinol Diabetes Obes 16:183-8. 2009
    ..To summarize the available data regarding the benefits of combination therapy with statins and ezetimibe in patients with cardiovascular disease...
  24. ncbi request reprint Atherosclerosis surrogate imaging trials come of age: for better or for worse?
    Michael H Davidson
    Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60654, USA
    Curr Cardiol Rep 10:521-5. 2008
    ..In light of the cost and time involved to complete morbidity trials demonstrating the benefit of potential antiatherosclerotic agents, surrogate imaging trials are necessary to expedite the regulatory approval process...
  25. ncbi request reprint Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial
    Theodore Mazzone
    Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Illinois College of Medicine, Chicago 60612, USA
    JAMA 296:2572-81. 2006
    ..While studies of relatively short duration have suggested that thiazolidinediones such as pioglitazone might reduce progression of CIMT in persons with diabetes, the results of longer studies have been less clear...
  26. ncbi request reprint Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups
    Michael H Davidson
    Chicago Center for Clinical Research, Chicago, Illinois 60610, USA
    Clin Cardiol 26:509-14. 2003
    ..In addition to lowering plasma levels of low-density lipoprotein cholesterol (LDL-C), statins also raise high-density lipoprotein cholesterol (HDL-C)...
  27. ncbi request reprint Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal
    Lynne T Braun
    The Rush Heart Institute, Rush Presbyterian St Luke s Medical Center, and College of Nursing Rush University, Chicago, Illinois, USA
    J Cardiovasc Nurs 18:44-9; quiz 75-6. 2003
    ..The conclusion was that all high-risk patients with LDL > or = 100 mg/dL should be treated with drug therapy with the goal of reducing LDL to < 100 mg/dL...
  28. ncbi request reprint Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia
    Michael H Davidson
    Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA
    Expert Opin Investig Drugs 11:125-41. 2002
    ..A starting dose of 10 mg will reduce LDL-C by approximately 50%, which should adequately treat most patients to within the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) goals...
  29. doi request reprint Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist
    Michael H Davidson
    Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Am J Cardiol 110:43B-49B. 2012
    ....
  30. doi request reprint Novel developments in omega-3 fatty acid-based strategies
    Michael H Davidson
    University of Chicago Pritzker School of Medicine, Chicago, IL 60654, USA
    Curr Opin Lipidol 22:437-44. 2011
    ..This review focuses on new prescription omega-3 fatty acid products in development and recently published data regarding omega-3 fatty acid effects on arrhythmias, heart failure, and platelet inactivation...
  31. doi request reprint Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice
    Michael H Davidson
    Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60610, USA
    Am J Med 122:S51-9. 2009
    ..The results from this study, which was conducted in a routine clinical practice setting, indicate the opportunities and the need for better monitoring and management of lipid levels in patients with atherosclerosis...
  32. ncbi request reprint Updating the assessment of cardiac risk: beyond Framingham
    William B Borden
    Division of Cardiology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    Rev Cardiovasc Med 10:63-71. 2009
    ..When used accordingly, the newer risk predictors build upon the Framingham framework to allow physicians and their patients to effectively minimize, or even avoid, the burden of cardiovascular disease...
  33. ncbi request reprint High-density lipoprotein metabolism: potential therapeutic targets
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 100:n32-40. 2007
    ....
  34. doi request reprint Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker
    Marshall A Corson
    Division of Cardiology, Department of Medicine, University of Washington, 325 9th Avenue, Seattle, WA 98104, USA
    Am J Cardiol 101:41F-50F. 2008
    ..Ultimately, Lp-PLA(2) may also be classified as a risk factor, but this should not detract from its utility today as a risk marker...
  35. ncbi request reprint Medical management of patients before the incidence of a cardiovascular event
    Michael H Davidson
    Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA
    J Clin Lipidol 3:315-21. 2009
    ..We sought to examine the diagnoses and medical management patterns of patients before the incidence of a cardiovascular (CV) event...
  36. ncbi request reprint Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study
    Michael H Davidson
    Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA
    Clin Ther 29:1354-67. 2007
    ..The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) has identified non-HDL-C as a secondary therapeutic target in these patients, but treatment goals may not be reached with statin monotherapy alone...
  37. ncbi request reprint Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease
    Michael H Davidson
    Pritzker School of Medicine, University of Chicago, Chicago, IL, USA
    Am Heart Hosp J 5:210-6. 2007
    ..This article reviews the strategies for targeting HDL cholesterol to optimize outcomes in CHD...
  38. doi request reprint A review of lipid management in primary and secondary prevention
    Ewa Dembowski
    The University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637, USA
    J Cardiopulm Rehabil Prev 29:2-12. 2009
    ..In many high-risk patients, statin monotherapy is unlikely to achieve goals, and combination therapy with other agents is a safe, effective, and optimal therapeutic approach...
  39. ncbi request reprint Management of dyslipidemia in patients with complicated metabolic syndrome
    Michael H Davidson
    Division of Preventive Cardiology, Department of Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Cardiol 96:22E-25E. 2005
    ..HIV lipodystrophy is associated with a marked risk of coronary artery disease (CAD), and more aggressive management of the dyslipidemia is likely necessary to improve the prognosis...
  40. ncbi request reprint Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol
    Kevin C Maki
    M D, Radiant Development, 515 N State St, 27th Floor, Chicago, IL 60610, USA
    J Am Coll Nutr 24:189-99. 2005
    ..To assess fasting lipid responses to a docosahexaenoic acid (DHA) supplement in men and women with below-average levels of high-density lipoprotein (HDL) cholesterol...
  41. ncbi request reprint Comparative effects of lipid-lowering therapies
    Michael H Davidson
    Radiant Research, Rush Medical College, Rush University Medical Center, Chicago, IL 60602, USA
    Prog Cardiovasc Dis 47:73-104. 2004
    ..This trend portends an ever-growing need for the aggressive and judicious use of different antilipidemic medication(s) in patients at risk for all forms of atherosclerotic vascular disease...
  42. ncbi request reprint Rosuvastatin safety: lessons from the FDA review and post-approval surveillance
    Michael H Davidson
    Rush Medical College, Rush University Medical Center, Chicago, Illinois, USA
    Expert Opin Drug Saf 3:547-57. 2004
    ..In the post-marketing surveillance for rosuvastatin, there have been reports of rhabdomyolysis, but the incidence rate, when corrected for prescription utilisation, is similar to other statins following initial approval...
  43. ncbi request reprint Newer pharmaceutical agents to treat lipid disorders
    Michael H Davidson
    Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, IL 60612, USA
    Curr Cardiol Rep 5:463-9. 2003
    ....
  44. ncbi request reprint Combination therapy in the management of complex dyslipidemias
    Michael H Davidson
    Rush Medical College, Rush University Medical Center, Chicago, Illinois, USA
    Curr Opin Lipidol 15:423-31. 2004
    ..This review discusses the need for comprehensive management of all abnormalities in a given patient's lipoprotein profile and for the use of combinations of anti-lipidemic medications, when indicated...
  45. ncbi request reprint A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d
    Michael H Davidson
    Radiant Research Chicago, Chicago, Illinois 60610, USA
    Clin Ther 25:2738-53. 2003
    ..The available statin drugs have similar pharmacodynamic properties but are not equal in low-density lipoprotein cholesterol (LDL-C)-lowering efficacy...
  46. ncbi request reprint Lipid responses in mildly hypertriglyceridemic men and women to consumption of docosahexaenoic acid-enriched eggs
    Kevin C Maki
    Radiant Research Chicago, 515 N State Street, Suite 2700, Chicago, IL 60610, USA
    Int J Vitam Nutr Res 73:357-68. 2003
    ..ordinary eggs (-12.3 vs. 2.1%; p = 0.027), and there was a greater increase for HDL cholesterol in the DHA-enriched vs. ordinary egg group (5.0 vs. 1.1%; p = 0.040)...
  47. ncbi request reprint Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia
    Michael H Davidson
    Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    Expert Opin Investig Drugs 11:125-41. 2002
    ..A starting dose of 10 mg will reduce LDL-C by approximately 50%, which should adequately treat most patients to within the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) goals...
  48. ncbi request reprint Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study
    Michael H Davidson
    Radiant Research Inc, Chicago, IL 60610, USA
    Clin Ther 27:715-27. 2005
    ..There is a need for new formulations that have improved bioavailability and eliminate the requirement for administration with food...
  49. ncbi request reprint Reducing residual risk for patients on statin therapy: the potential role of combination therapy
    Michael H Davidson
    Rush Medical College, Rush University Medical Center, Chicago, Illinois 60610, USA
    Am J Cardiol 96:3K-13K; discussion 34K-35K. 2005
    ..This article discusses the role of combination therapy in managing CAD and in achieving optional targets in high-risk patient populations...
  50. ncbi request reprint Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance
    Michael H Davidson
    Chicago Center for Clinical Research, Chicago, Illinois, USA
    Am J Cardiol 89:8C-20C; discussion 20C-22C. 2002
    ..The use of global risk scoring aids, including the Palm Pilot cholesterol risk calculators, can improve guideline adherence and provide education and motivation to patients to maintain compliance...
  51. ncbi request reprint Differences between clinical trial efficacy and real-world effectiveness
    Michael H Davidson
    Rush University Medical Center, 1725 W Harrison St, Ste 1159, Chicago, IL 60612, USA
    Am J Manag Care 12:S405-11. 2006
    ..This review sets forth compelling data that starting patients on or switching to high-efficacy LDL-C-lowering therapy enhances achievement of NCEP ATP III guidelines outside of the controlled trial setting...
  52. ncbi request reprint Lipid-lowering effects of statins: a comparative review
    Michael H Davidson
    Radiant Research, Chicago, IL, USA
    Expert Opin Pharmacother 7:1701-14. 2006
    ....
  53. ncbi request reprint Squalene synthase inhibition: a novel target for the management of dyslipidemia
    Michael H Davidson
    Radiant Research, 515 N State Street, Suite 2700, Chicago, IL 60610, USA
    Curr Atheroscler Rep 9:78-80. 2007
    ..Human clinical trial data with TAK-475, a novel and potent inhibitor of squalene synthase, have not yet been published...
  54. ncbi request reprint Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
    Michael H Davidson
    Department of Cardiology, Rush University Medical College, 60610, USA
    Clin Cardiol 29:268-73. 2006
    ....
  55. ncbi request reprint Statin safety: an appraisal from the adverse event reporting system
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 97:32C-43C. 2006
    ..Postrosuvastatin AE reporting patterns were comparable to those seen with other statins and did not resemble cerivastatin...
  56. pmc A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-technology (NEPTUNE) II survey
    K C Maki
    Radiant Development, Chicago, Illinois, USA
    Can J Cardiol 22:315-22. 2006
    ..The United States' National Cholesterol Education Program (NCEP) Adult Treatment Panel III and the Canadian Working Group on Hypercholesterolemia and Other Dyslipidemias (CWG) have each issued guidelines for the treatment of dyslipidemia...
  57. ncbi request reprint Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions
    Michael H Davidson
    Rush University, Preventive Cardiology Center, Rush Presbyterian St Luke s Medical Center, 515 State Street, Suite 2700, Chicago, IL, USA
    Expert Opin Drug Saf 5:145-56. 2006
    ..The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study in 10,000 patients with Type 2 diabetes mellitus is testing the efficacy and safety of fenofibrate/statin combination...
  58. ncbi request reprint Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids
    Michael H Davidson
    Radiant Research and Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 98:27i-33i. 2006
    ..These combined effects support the use of omega-3 fatty acids as a valuable clinical tool for the treatment of hypertriglyceridemia...
  59. ncbi request reprint Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events
    Michael H Davidson
    Department of Preventive Cardiology, Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA
    Curr Atheroscler Rep 5:418-22. 2003
  60. ncbi request reprint Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
    Michael H Davidson
    Radiant Development, Chicago, Illinois, USA
    Am J Cardiol 96:556-63. 2005
    ..Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals...
  61. doi request reprint Focusing on high-density lipoprotein for coronary heart disease risk reduction
    Michael H Davidson
    Department of Medicine, Section of Cardiology, Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA
    Cardiol Clin 29:105-22. 2011
    ..This article presents a review of the biologic actions of HDL that can serve as a potential basis for antiatherosclerotic activity and discusses strategies for targeting HDL for CHD risk reduction...
  62. doi request reprint Therapies targeting exogenous cholesterol uptake: new insights and controversies
    Michael H Davidson
    Clinical Professor, Director of Preventive Cardiology, The University of Chicago Pritzker School of Medicine, 515 North State Street, Suite 2700, Chicago, IL 60654, USA
    Curr Atheroscler Rep 13:95-100. 2011
    ....
  63. doi request reprint A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia
    Michael H Davidson
    The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    Am J Cardiovasc Drugs 10:305-14. 2010
    ....
  64. doi request reprint Novel targets that affect high-density lipoprotein metabolism: the next frontier
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 104:52E-7E. 2009
    ..This article reviews current options for the therapeutic management of HDL cholesterol, including discussion of novel agents aimed at reducing cardiovascular disease risk in patients with low levels of HDL cholesterol...
  65. doi request reprint Reducing cardiovascular risk: trends in risk, risk assessment, and cholesterol management
    Michael H Davidson
    Rush University Medical Center, Chicago Center for Clinical Research, 515 N State St, Suite 2700, Chicago, IL 60610 4324, USA
    Postgrad Med 116:7-12. 2004
    ..An increasing number of factors are included in risk assessment, and the recommended intensity of intervention with lipid-lowering treatment continues to increase among patients considered to be at high risk...
  66. ncbi request reprint Novel nonstatin strategies to lower low-density lipoprotein cholesterol
    Michael H Davidson
    Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60654, USA
    Curr Atheroscler Rep 11:67-70. 2009
    ..Although each of these novel therapies effectively lowers LDL-C, challenges remain in the clinical development to assess long-term safety...
  67. ncbi request reprint Global risk management in patients with type 2 diabetes mellitus
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Am J Cardiol 99:41B-50B. 2007
    ..Global risk reduction with aggressive low-density lipoprotein reduction and through the additional normalization of glucose levels and blood pressure can help to reduce absolute risk in this very high-risk population...
  68. ncbi request reprint Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors
    Michael H Davidson
    Rush University Medical Center, 1725 West Harrison St, Ste 1159, Chicago, IL 60612, USA
    Am J Manag Care 13:S260-9. 2007
    ..Emphasis is on newer data regarding the effect of statins in retarding progression of atherosclerosis or even inducing regression of atherosclerosis...
  69. doi request reprint Niacin use and cutaneous flushing: mechanisms and strategies for prevention
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60610 4310, USA
    Am J Cardiol 101:14B-19B. 2008
    ..Because niacin has recognized cardiovascular benefits, promoting patient awareness of factors that can minimize niacin-induced flushing can help enhance the tolerability of this valuable dyslipidemic agent...
  70. doi request reprint Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637 5415, USA
    Am J Cardiol 101:1B-2B. 2008
  71. doi request reprint Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction
    Michael H Davidson
    The University of Chicago Pritzker School of Medicine, 515 N State Street, Suite 2700, Chicago, IL 60654, USA
    J Clin Lipidol 7:S11-5. 2013
    ..It is expected to meet an important clinical need for patients unable to achieve adequate LDL-C-lowering with currently available therapies...
  72. ncbi request reprint The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review
    Michael H Davidson
    University of Chicago, Pritzker School of Medicine, Executive Medical Director, Radiant Research, Chicago, IL, USA
    Expert Opin Pharmacother 8:2569-78. 2007
    ..This article reviews the clinical efficacy and use of colesevelam HCL for the management of dyslipidemia...
  73. ncbi request reprint Safety of aggressive lipid management
    Michael H Davidson
    Radiant Research, Rush University Medical Center, Chicago, Illinois, USA
    J Am Coll Cardiol 49:1753-62. 2007
    ..In order to optimize patient outcomes, clinicians should be aware of specific patient characteristics, such as advancing age, gender, body mass index, or glomerular filtration rate, which predict muscle and hepatic statin toxicity...
  74. ncbi request reprint Type 2 diabetes and cardiovascular disease: reducing the risk
    David W Bartels
    University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA
    J Manag Care Pharm 13:S2-15; quiz S16-7. 2007
    ..Type 2 diabetes (T2DM) is a major risk factor for developing cardiovascular disease (CVD). The growing epidemic of T2DM has contributed to CVD becoming the leading cause of morbidity and mortality in the United States...
  75. doi request reprint Cardiovascular effects of glucagonlike peptide-1 agonists
    Michael H Davidson
    Section of Preventive Cardiology, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Am J Cardiol 108:33B-41B. 2011
    ..This article presents an overview of the CV effects of GLP-1 agonists, highlighting implications for the management of patients with diabetes and heart disease...
  76. doi request reprint A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia
    Michael H Davidson
    The University of Chicago Pritzker School of Medicine, 515 North State Street, Suite 2700, Chicago, IL 60654, USA
    J Clin Lipidol 5:76-81. 2011
    ..This review summarizes the clinical data regarding the efficacy and safety of bile acid sequestrants in this specialized population...
  77. ncbi request reprint Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia
    Michael H Davidson
    Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60654, USA The University of Chicago Pritzker School of Medicine, Chicago, IL, USA
    J Clin Lipidol 3:332-40. 2009
    ..To date, limited information has been published regarding the effects of omega-3 fatty acid consumption on lipoprotein particle concentrations...
  78. doi request reprint Update on CETP inhibition
    Michael H Davidson
    The University of Chicago Pritzker School of Medicine, 515 North State Street, Suite 2700, Chicago, IL 60654, USA
    J Clin Lipidol 4:394-8. 2010
    ..CETP inhibition as a therapeutic strategy remains a valid option to be tested with a CETP inhibitor that does not share torcetrapib's off-target effects...
  79. doi request reprint Introduction. U.S. incidence of coronary artery disease
    Michael H Davidson
    Pritzker School of Medicine, University of Chicago, 515 North State Street, Chicago, IL 60610, USA
    Am J Cardiol 101:1F-2F. 2008
  80. doi request reprint Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose
    Michael H Davidson
    Preventive Cardiology, The University of Chicago Medicine, Chicago, IL 60637 Radiant Development, Radiant Research Inc, 515 N State Street, Suite 2700, Chicago, IL 60654
    J Clin Lipidol 7:423-32. 2013
    ..Colesevelam has the unique dual approvals to lower low-density lipoprotein cholesterol (LDL-C) and to improve glycemic control in type 2 diabetes mellitus...
  81. ncbi request reprint Rosuvastatin in elderly patients
    Michael H Davidson
    Preventive Cardiology, The University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
    Drugs Aging 24:933-44. 2007
    ..As yet, however, cardiovascular endpoint data for rosuvastatin are not available...
  82. ncbi request reprint Safety considerations with fibrate therapy
    Michael H Davidson
    Rush University Medical Center, Chicago, Illinois, USA
    Am J Cardiol 99:3C-18C. 2007
    ....
  83. doi request reprint National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events
    George Bakris
    Department of Medicine, University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637, USA
    Kidney Int 78:726-36. 2010
    ..This paper summarizes the results of a consensus conference utilizing a patient case to discuss the integrated management of hypertension, kidney disease, dyslipidemia, diabetes, and heart failure across disciplines...
  84. ncbi request reprint Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults
    Kevin C Maki
    Radiant Research, Chicago, IL, USA
    Am J Clin Nutr 85:724-34. 2007
    ..Lowering the dietary glycemic load and increasing protein intake may be advantageous for weight management...